Your session is about to expire
← Back to Search
[18F]NAV4694 for Alzheimer's Disease
Phase 2
Waitlist Available
Research Sponsored by Navidea Biopharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 25 minutes post injection
Awards & highlights
Study Summary
This is a phase 2, open-label, multiple-center, non-randomized single dose study to assess the safety and efficacy of [18F]NAV4694 PET imaging in detecting beta-amyloid plaque in the brain in subjects with probable AD compared with healthy volunteers.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 25 minutes post injection
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~25 minutes post injection
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
[18F]NAV4694 PET visual assessment by centralized readers
Secondary outcome measures
Assess changes in laboratory values after a single dose of [18F]NAV4694
Assess the incidence of adverse events after a single dose of [18F]NAV4694
Determine correlation of neuro-psychiatric tests with [18F]NAV4694 imaging
+1 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: [18F]NAV4694Experimental Treatment1 Intervention
Single intravenous injection of 8.1 millicuries of [18F]NAV4694
Find a Location
Who is running the clinical trial?
Navidea BiopharmaceuticalsLead Sponsor
20 Previous Clinical Trials
1,838 Total Patients Enrolled
Cornelia Reininger, M.D., PhDStudy DirectorNavidea Biopharmaceuticals
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger